Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Annals of General Psychiatry
Published in: Annals of General Psychiatry 1/2016

Open Access 01-12-2016 | Primary research

Pharmacotherapy and group cognitive behavioral therapy enhance follow-up treatment duration in gambling disorder patients

Authors: Sam-Wook Choi, Young-Chul Shin, HyunChul Youn, Se-Won Lim, Juwon Ha

Published in: Annals of General Psychiatry | Issue 1/2016

Login to get access

Abstract

Background

Longer treatment duration is important for the successful treatment of gambling disorder (GD). This retrospective study investigated the factors and interventions that might enhance treatment duration in GD patients in South Korea.

Methods

A total of 758 outpatients with a primary diagnosis of GD, who were treated in a clinical practice from 2002 to 2011, were assessed by retrospective chart review. We compared the treatment duration according to pharmacotherapy and group cognitive behavioral therapy (CBT).

Results

Pharmacotherapy contributed to a longer duration of treatment maintenance, despite the patients’ gambling severity (p < 0.001). Participation in group CBT (p < 0.001) and antidepressants (p = 0.009) were associated with a longer treatment duration after adjusting for age, depression, and gambling severity. The treatment maintenance duration was the longest in those receiving combined antidepressant pharmacotherapy and group CBT (F = 35.79, p < 0.001).

Conclusions

Group CBT and antidepressants seem to enhance treatment follow-up duration in GD patients. Additional studies are needed to advance GD prevention and treatment strategies.
Literature
1.
Petry NM. Pathological gambling: etiology, comorbidity, and treatment. Washington: American Psychological Association; 2012.
2.
American Psychiatric Association. Diagnostic and statistical manual of mental disorders: DSM-5. 5th ed. Washington: American Psychiatric Publishing; 2013.
3.
Soberay AD, Grimsley P, Faragher JM, Barbash M, Berger B. Stages of change, clinical presentation, retention, and treatment outcomes in treatment-seeking outpatient problem gambling clients. Psychol Addict Behav. 2014;28:414–9.CrossRefPubMed
4.
Egorov AI. Modern treatment approaches to gambling. Zhurnal Nevrol Psikhiatrii Im SS Korsakova Minist Zdr Meditsinskoi Promyshlennosti Ross Fed Vserossiiskoe Obshchestvo Nevrol Vserossiiskoe Obshchestvo Psikhiatrov. 2014;114:46–52.
5.
6.
7.
Leblond J, Ladouceur R, Blaszczynski A. Which pathological gamblers will complete treatment? Br J Clin Psychol. 2003;42:205–9.CrossRefPubMed
8.
Blanco C, Petkova E, Ibáñez A, Sáiz-Ruiz J. A pilot placebo-controlled study of fluvoxamine for pathological gambling. Ann Clin Psychiatry. 2002;14:9–15.CrossRefPubMed
9.
Grant JE, Kim SW, Kuskowski M. Retrospective review of treatment retention in pathological gambling. Compr Psychiatry. 2004;45:83–7.CrossRefPubMed
10.
Knezevic B, Ledgerwood DM. Gambling severity, impulsivity, and psychopathology: comparison of treatment- and community-recruited pathological gamblers. Am J Addict. 2012;21:508–15.CrossRefPubMed
11.
Rosenberg O, Dinur LK, Dannon PN. Four-year follow-up study of pharmacological treatment in pathological gamblers. Clin Neuropharmacol. 2013;36:42–5.CrossRefPubMed
12.
Lupi M, Martinotti G, Acciavatti T, Pettorruso M, Brunetti M, Santacroce R, et al. Pharmacological treatments in gambling disorder: a qualitative review. BioMed Res Int. 2014;2014:537306.CrossRefPubMedPubMedCentral
13.
Dieterich M, Irving CB, Park B, Marshall M. Intensive case management for severe mental illness. Cochrane Database Syst Rev. 2010;10:CD007906.PubMed
14.
American Psychiatric Association. Diagnostic and statistical manual of mental disorders, text revision. 4th ed. Washington: American Psychiatric Association; 2000.
15.
Choi WC, Kim KB, Oh DY, Lee TK. A preliminary study on standardization of korean form of south oaks gambling screening. J Korean Acad Addict Psychiatry. 2001;5:46–52.
16.
Shin YC, Choi SW, Ha J, Mok JY, Lim SW, Choi JS, et al. Age of pathological gambling onset: clinical and treatment-related features. J Addict Med. 2014;8:205–10.CrossRefPubMed
17.
18.
Ha J, Shin YC. Treatment of pathological gambling. J Korean Acad Addict Psychiatry. 2013;17:24–31.
19.
20.
Potenza MN. Pathological gambling: a clinical guide to treatment. 1st ed. Washington: American Psychiatric Publishing; 2004.
21.
Ladouceur R, Sévigny S. Structural characteristics of video lotteries: effects of a stopping device on illusion of control and gambling persistence. J Gambl Stud. 2005;21:117–31.CrossRefPubMed
22.
Kim HJ, Kim JH, Shin YC, Shin HC, Grant JE, Lee TK. The reliability and validity of the Korean translation of the Gambling Symptom Assessment Scale (KG-SAS). J Korean Neuropsychiatr Assoc. 2005;44:682–9.
23.
Sung HM, Kim JB, Park YN, Bai DS, Lee SH, Ahn HN. A study on the reliability and the validity of Korean version of the Beck depression inventory-II (BDI-II). J Korean Soc Biol Ther Psychiatry. 2008;14:201–12.
24.
Weatherly JN, Sauter JM, King BM. The “big win” and resistance to extinction when gambling. J Psychol. 2004;138:495–504.CrossRefPubMed
25.
Rosenberg O, Dinur LK, Dannon PN. Four-year follow-up study of pharmacological treatment in pathological gamblers. Clin Neuropharmacol. 2013;36:42–5.CrossRefPubMed
26.
Iancu I, Lowengrub K, Dembinsky Y, Kotler M, Dannon PN. Pathological gambling: an update on neuropathophysiology and pharmacotherapy. CNS Drugs. 2008;22:123–38.CrossRefPubMed
27.
Toneatto T, Brands B, Selby P. A randomized, double-blind, placebo-controlled trial of naltrexone in the treatment of concurrent alcohol use disorder and pathological gambling. Am J Addict. 2009;18:219–25.CrossRefPubMed
28.
Grant JE, Kim SW, Hartman BK. A double-blind, placebo-controlled study of the opiate antagonist naltrexone in the treatment of pathological gambling urges. J Clin Psychiatry. 2008;69:783–9.CrossRefPubMed
29.
Grant JE, Potenza MN. Escitalopram treatment of pathological gambling with co-occurring anxiety: an open-label pilot study with double-blind discontinuation. Int Clin Psychopharmacol. 2006;21:203–9.CrossRefPubMed
30.
Oei TPS, Raylu N, Casey LM. Effectiveness of group and individual formats of a combined motivational interviewing and cognitive behavioral treatment program for problem gambling: a randomized controlled trial. Behav Cogn Psychother. 2010;38:233–8.CrossRefPubMed
31.
32.
Wood TE, Englander-Golden P, Golden DE, Pillai VK. Improving addictions treatment outcomes by empowering self and others. Int J Ment Health Nurs. 2010;19:363–8.CrossRefPubMed
33.
Pallesen S, Molde H, Arnestad HM, Laberg JC, Skutle A, Iversen E, et al. Outcome of pharmacological treatments of pathological gambling: a review and meta-analysis. J Clin Psychopharmacol. 2007;27:357–64.CrossRefPubMed
34.
Lobo DSS, Quilty LC, Martins SS, Tavares H, Vallada H, Kennedy JL, et al. Pathological gambling subtypes: a comparison of treatment-seeking and non-treatment-seeking samples from Brazil and Canada. Addict Behav. 2014;39:1172–5.CrossRefPubMed
35.
Kushnir V, Cunningham JA, Hodgins DC. A prospective natural history study of quitting or reducing gambling with or without treatment: protocol. JMIR Res Protoc. 2013;2:e51.CrossRefPubMedPubMedCentral
36.
Klingemann H, Carter-Sobell L. Promoting self-change from addictive behaviors: practical implications for policy, prevention, and treatment. 1st ed. Berlin: Springer; 2007.CrossRef
Metadata
Title
Pharmacotherapy and group cognitive behavioral therapy enhance follow-up treatment duration in gambling disorder patients
Authors
Sam-Wook Choi
Young-Chul Shin
HyunChul Youn
Se-Won Lim
Juwon Ha
Publication date
01-12-2016
Publisher
BioMed Central
Published in
Annals of General Psychiatry / Issue 1/2016
Electronic ISSN: 1744-859X
DOI
https://doi.org/10.1186/s12991-016-0107-1

Other articles of this Issue 1/2016

Annals of General Psychiatry 1/2016 Go to the issue

Erratum

Erratum to: Integrating technology into cognitive behavior therapy for adolescent depression: a pilot study

Primary research

Resilience and burnout status among nurses working in oncology

Primary research

Development and validation of a stock addiction inventory (SAI)

Primary research

Intact social cognitive processes in outpatients with anorexia nervosa: a pilot study

Primary research

Link of dysfunctional attitudes with the negative self-model

Primary research

Multi-regression analysis revealed a relationship between l-serine and methionine, a component of one-carbon metabolism, in the normal control but not in the schizophrenia